Advanced BioHealing is an industry leader in the science of regenerative medicine. The company is focused on the commercialization of cell-based and tissue-engineered products including two that have FDA approval for marketing: Dermagraft, for diabetic foot ulcers and TransCyte, to treat full and partial thickness burns. The company’s development pipeline includes a next-generation bioengineered wound therapy for which two Investigational Device Exemption (IDE) applications have been conditionally approved by the FDA.
Ultimately, the goal of Advanced BioHealing is to be a clearinghouse for advanced wound technologies and to offer a portfolio of complementary products that accelerate healing or improve cosmetic and functional outcomes.
Website:
www.advancedbiohealing.com
Safeguard Partner Company since 2007